IRMD IRADIMED CORP Insider Trading

CEO Roger E. Susi sold 7,500 shares for $691,043.76 under pre-arranged 10b5-1 plan; retains 2.16M shares

Roger E. Susi executed 4 separate sales totaling 7,500 shares for $691,043.76 at blended average price $92.14 across May 26-27, 2026. As a pre-arranged 10b5-1 trading plan adopted on 2025-11-05, this transaction was scheduled rather than discretionary. The CEO's holdings decreased by only 0.3%, leaving him with 2,165,000 shares post-transaction. At IRMD, Susi's 5 prior sales produced modest positive returns (ranging 3.6% to 6.8% at the 90-day mark), though this historical pattern provides limited predictive value for a pre-scheduled trade. The company shows solid fundamentals with annual revenue growth of 14.4% and net income of $5,818,000, though the stock trades at a P/E of 49.72, well above typical industrial or medical-device peers.

CEO Roger E. Susi sold 7,500 shares for $657,264.82 via scheduled 10b5-1 plan; stock down 2.7% in 30 days, 10.4% in 90 days.

Susi Roger E. executed 6 separate sales totaling 7,500 shares for $657,264.82 across two trading days (May 18–19, 2026), with transaction prices ranging from $85.95 to $88.65 and a blended average of $87.64. This sale reduces his holdings by 0.3% (from 2.18M to 2.17M shares) and is governed by a pre-arranged 10b5-1 trading plan adopted on 2025-11-05, making this a scheduled transaction rather than discretionary activity. The current stock price of $90.40 is 16.2% below the 52-week high of $107.90, and the stock has declined 10.4% over the past 90 days and 2.7% over the past 30 days. His prior sales at IRMD have posted positive returns in both 30- and 90-day windows (range: +1.7% to +4.4%), while his cross-ticker track record shows an average 90-day return of +1.2%, though these backward-looking returns do not inform the timing of this scheduled transaction. The company shows solid fundamentals with revenue of $21,979,000.00, net income of $5,818,000.00, annual growth of 14.4%, and a P/E of 48.86.

CEO Susi Roger E. sells 7,500 IRMD shares for ~$631K; stock off 20% from 52-week highs; all five prior sales poorly timed.

Susi Roger E., IRMD's CEO, President, and Chairman, executed five separate sales totaling 7,500 shares in a two-day window. The stock is currently trading well below its 52-week high, down sharply over both the prior month and quarter. Despite this weakness, Susi's track record at this ticker has been consistently poor: all five of his previous sales at IRMD were followed by gains in the stock, meaning he exited too early each time. This filing repeats that pattern—adding to six prior open-market sales at this company within the measurement window. The company itself remains profitable with solid revenue growth, so the selling does not reflect fundamental distress. Without visibility into Susi's personal liquidity needs or estate planning, the repeated exits during a period of stock decline raise a question: is the CEO unwinding shares regardless of price momentum, or does he see value better realized elsewhere?

CEO Susi Roger E. sells 7,500 shares for $643K; 12th IRMD sale in 36 months, continuing an all-sell pattern with historically poor timing.

Susi Roger E., the CEO, President, and Chairman of IRADIMED, sold 7,500 shares across seven transactions in early May for a combined $643K, bringing his total open-market sales at this company to twelve over the past three years—with zero purchases during the same period. His track record on prior IRMD sales is notably poor: every one of his five prior sales at this ticker was followed by the stock rising, meaning he consistently exited too early. The current sale occurs while the company remains profitable and growing revenue in the double digits, though the stock is trading about 21% below its 52-week high and down roughly 14% over the past quarter. Roger E.'s three-year pattern of sell-only activity, combined with universally mistimed prior exits at this stock, suggests a mechanical liquidation pattern rather than tactical conviction about near-term downside—and his historical track record offers little evidence he successfully times these sales to protect value.

CEO Susi Roger E. sells 7,500 shares (7 separate sales, 2026-04-27 to 2026-04-28) for $657,709.12 under pre-arranged 10b5-1 plan.

CEO Susi Roger E. executed 7 separate sales totaling 7,500 shares for $657,709.12 across two days (2026-04-27 to 2026-04-28) at a blended average price of $87.69, with individual transaction prices ranging from $84.13 to $89.70. This sale reduces his holdings from 2,202,500 shares to 2,195,000 shares, representing a -0.3% reduction in his position. The transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-11-05, indicating this was a scheduled disposition rather than a discretionary trade. The modest size relative to his total post-transaction holdings of 2,195,000 shares and the plan-driven nature of the execution are consistent with routine executive portfolio management under an established schedule.

CEO Susi Roger E. sold 7,500 shares for $694,124.08 across 6 transactions on 2026-04-20 to 2026-04-21 under pre-arranged 10b5-1 plan adopted 2025-11-05.

Susi Roger E., CEO, President, and Chairman of IRRADIMED CORP (IRMD), executed 6 separate sales totaling 7,500 shares for $694,124.08 at a blended average price of $92.55, reducing holdings from 2,210,000 shares to 2,202,500 shares (-0.3% of pre-transaction holdings). This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-11-05, meaning the sales were scheduled in advance and not discretionary decisions made in response to current market conditions. The magnitude of the sale represents a minimal reduction in the CEO's total stake, and the structured, scheduled nature of the disposition limits any inference about near-term business outlook or conviction.

CEO Roger Susi sold 7,500 shares at blended avg $92.96 for $697,189.21 across 5 transactions on Apr 13-14.

CEO, President, and Chairman Susi Roger E. executed five separate sales totaling 7,500 shares for $697,189.21 at prices ranging from $91.84 to $94.55 across two trading days, reducing holdings from 2,217,500 to 2,210,000 shares (-0.3%). The sales occurred as IRMD trades at $93.05, near the lower end of its 52-week range ($50.10–$105.15), having declined 8.5% over 30 days and 9.3% over 90 days. The company reports strong fundamentals: $21.2M quarterly revenue, $5.6M net income, 14.4% annual revenue growth, and a P/E of 48.72, suggesting the stock is priced at a premium despite recent weakness. The insider remains heavily invested with 2.21M shares post-transaction, and his cross-ticker track record shows an average 30-day return of -4.8% following prior sells, indicating limited historical success in timing market exits. No timing pattern can be assessed for his prior five IRMD trades at this ticker given they were all recent and outcomes are not yet measurable.

CEO Susi Roger E. sold 7,500 shares at blended avg $95.63 for $717,207.59 across 5 transactions on Apr 6-7, 2026.

CEO Susi Roger E. executed 5 separate sales totaling 7,500 shares for $717,207.59 over two trading days (April 6-7, 2026), reducing his holdings from 2,225,000 shares to 2,217,500 shares (-0.3%). The sales occurred near the 52-week high ($105.15), with the blended average price of $95.63 above the current price of $93.49, suggesting favorable execution timing in absolute terms. However, the stock has declined 5.3% over the past 30 days and is currently -11.1% from its 52-week high. His cross-ticker track record shows 20 prior sells with an average 30-day return of -1.3%, and at IRMD specifically, he executed 5 prior sells on March 24 and March 30 (outcomes not yet measurable). The modest share reduction (-0.3%) relative to his 2.22M-share position suggests this was not a substantial liquidation, and the company maintains solid fundamentals with revenue of $21,202,064 and net income of $5,576,652 in the latest quarter.

CEO Roger E. Susi sells 7,500 shares of IRMD at blended average price $95.02 for $712,614.05

Susi Roger E., CEO, President, and Chairman of IRADIMED CORP, executed 3 separate sales on 2026-03-30 totaling 7,500 shares for $712,614.05. The sales occurred at prices ranging from $94.81 to $96.53, with a blended average price of $95.02, while the stock's current price stands at $96.54. This disposition represents a 0.3% reduction in his pre-transaction holdings of 2,232,500 shares, leaving post-transaction holdings of 2,225,000 shares. The company recently reported quarterly revenue of $21,202,064.00 and net income of $5,576,652.00, with annual revenue growth of 14.4%. The timing of this sale merits observation: the stock is trading 8.2% below its 52-week high of $105.15 and has declined 6.9% over the preceding 30 days, yet the CEO has executed a discrete open-market sale at prices near current levels rather than at recent highs. Additionally, this sale is part of a broader pattern—the SAME-TICKER HISTORY section indicates 5 prior sales at IRMD within the preceding week (2026-03-23 and 2026-03-24), all executed in rapid succession, suggesting a concentrated disposition program rather than a sporadic trade.

CEO Susi Roger E. sold 7,500 shares across 5 transactions (2026-03-23 to 2026-03-24) for $752,609.20; current price $101.78.

CEO Susi Roger E. executed 5 separate sales totaling 7,500 shares for $752,609.20 between March 23 and March 24, 2026, at an average price of $100.35 per share. The sales represent a modest -0.3% reduction in his 2.24M share holding, leaving him with 2,232,500 shares post-transaction. While the current stock price of $101.78 sits only 3.2% below its 52-week high of $105.15 and the company shows solid fundamentals (14.4% annual revenue growth, $5.6M net income, market cap $1.3B), the timing is notable: this marks the fifth sale by the CEO within a 14-day window (three prior sells on March 16-17 and one on March 10, before this latest filing). His cross-ticker track record shows 12 prior sells with an average 30-day return of -0.8%, though same-ticker outcomes remain unmeasurable at this stage. The concentrated selling activity warrants observation as to whether it reflects portfolio rebalancing or other considerations.